Navigation Links
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
Date:5/21/2008

TOKYO, May 21 /PRNewswire/ -- Daiichi Sankyo Co., Ltd. announced today that it has entered into an agreement to acquire the privately held firm, U3 Pharma AG, a German biotechnology company focusing on research into antibodies for the treatment of cancer.

Daiichi Sankyo will purchase 100 percent of the stock and make a one-time payment of 150 million Euros ($235 million dollars) for the company. Closure of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and customary closing conditions.

U3 Pharma, which is based in Martinsried, Germany, was founded by Professor Axel Ullrich of the Max Planck Institute of Biochemistry, whose pioneering gene technology-based and oncology-focused research led to the development of the oncology blockbusters Herceptin(R) and Sutent(TM)*. U3 Pharma was established in 2001 and currently employs 27 people, the majority of whom work directly in research and development.

U3 Pharma's investors include Alta Partners, Atlas Venture, E. de Rothschild Investment Partners, Life Science Partners and Karsten Henco, as well as private individuals from the biotech and pharmaceutical industries.

U3 Pharma's pipeline of novel targeted therapeutics includes programs focusing on fully-human antibodies as potential therapies for breast, lung and colorectal cancers, among others. The company's lead product, which is being co-developed with Amgen, is U3-1287 (AMG 888), the first fully-human anti-HER3 monoclonal antibody (mAb) to inhibit oncogenic signaling and tumor proliferation. The companies intend to initiate clinical development of this compound this year.

Daiichi Sankyo's current novel therapeutics portfolio for worldwide commercialization includes CS-1008, an oncologic agent to combat malignant neoplasms, which is in Phase 2. For commercialization only in Japan, Daiichi Sankyo has the rights to market denosumab, or AMG 162, which is licensed from Amgen. In Japan, t
'/>"/>

SOURCE Daiichi Sankyo Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... synthetic biology covers the designing and engineering of completely ... the redesigning of natural biological systems that provide improved ... form of extreme genetic engineering because it not only ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Immunomic Therapeutics, ... researchers to further develop potential treatments for glioblastoma multiforme ... in combination with their patented vaccine platform, LAMP-vax. ... University, are based on the work of John H. ... at The Preston Robert Tisch Brain Tumor Center at ...
(Date:7/28/2014)... Appistry, Inc. , a leading provider ... of genomics to next-generation medicine, announced today its judging ... , Two Appistry staff will be joined by ... Genome Resources, and Mr. Neil Miller, director of informatics ... Rounding out the panel are Appistry’s Dr. Richard Mazzarella, ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... (NYSE: SGP ) will provide a live ... Ph.D., executive vice president and president, Schering-Plough Research Institute, ... San Francisco on Monday, Jan. 12, at approximately 3:30 ... to talk about the company,s R&D pipeline and select ...
... 9 Endo Pharmaceuticals (Nasdaq: ENDP ) announced ... Endo, will present a corporate update at the J.P. Morgan ... 10:30 a.m. Pacific Time. The conference will be held ... live audio Webcast of the presentation may be accessed on ...
... Ireland, January 9 Azur Pharma Limited ... exclusive U.S. marketing rights,for Niravam(R) (alprazolam orally ... (baclofen,orally disintegrating tablets) and Fluxid(TM) (famotidine orally,disintegrating ... were not,disclosed. , ...
Cached Biology Technology:Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2
(Date:7/25/2014)... Before the colonial era, 100,000s of people lived on ... cultures manipulated fire to control the availability of plants ... tribes continue to use fire to maintain desired habitat ... the U.S. Forest Service,s Pacific Southwest Station, will lead ... National Wildfire Refuge during the Ecological Society of America,s ...
(Date:7/25/2014)... study published online in the International Journal of ... to preventing cervical cancer based on findings showing successful ... of a discrete population of cells in the cervix. ... looked at squamocolumnar junction cells, or SCJ cells. These ... implicated as the origins of cervical cancer. A research ...
(Date:7/25/2014)... the way for the development of new lines of barley ... production is second only to wheat with 7-8 million tonnes ... diseases of barley. , Senior Research Scientist Dr Alan Little ... the cell walls of barley plants that block the penetration ... the ARC Centre of Excellence in Plant Cell Walls in ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Clearing cells to prevent cervical cancer 2New hope for powdery mildew resistant barley 2
... new role for a key cancer protein, a finding that ... variety of tumors. Many cancers are driven in part ... to escape growth controls and proliferate abnormally. In the new ... , researchers discovered that cyclin D1 also helps cancer cells ...
... by the Biotechnology and Biological Sciences Research Council (BBSRC)-led ... an enzyme in bacteria which could be used to ... in the 14 June Issue of the American Chemical ... out by teams at the Universities of Warwick and ...
... (June 9, 2011) − Mice born to mothers who are ... to develop intestinal tumors, report scientists at the Jean Mayer ... Tufts University. Previous research in humans and mice ... the prevention of colorectal cancer. Using a mouse model of ...
Cached Biology News:Cancer protein discovery may aid radiation therapy 2Cancer protein discovery may aid radiation therapy 3First wood-digesting enzyme found in bacteria could boost biofuel production 2B vitamins in mother's diet reduce colorectal cancer risk in offspring 2
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... standard for whole-blood clinical diagnostic work in ... less, this analyzer makes precise glucose measurements ... precise lactate measurements of whole blood, plasma, ... option allows you to have glucose results ...
... The first high-density serum biomarker chip to ... proteins. An antibody chip containing 120 human ... that enables biomarker discovery scientists to study ... benefits of therapy and the likelihood of ...
... description: The Costar strip ejector is a ... of Costar strips from their holder. Linkage: ... number, created to easily match Cornings product ... order under the old Sigma-Aldrich number (Z71,314-7) ...
Biology Products: